The TruePath CTO device features a ultra-low 0.018 profile, with a rotating diamond-coated tip designed to break through occluded peripheral arteries and helps in placing a conventional guidewires.
The CTO device also has an optional extension wire for catheter exchange and increase the working length beyond 300 cm.
The distal tip when once positioned rotates at 13,000 rotations per minute (rpm) and drills through calcified lesions and other fibrous blockages.
Boston Scientific Peripheral Interventions division president Jeff Mirviss said this crossing device further expands their growing peripheral interventions portfolio and provides physicians an option to treat patients with challenging lesions in the lower extremities who may have otherwise faced amputation.
"Addressing this growing health problem through the use of less-invasive devices could greatly improve patient care and ultimately save limbs," Mirviss said.
Boston said it purchased the TruePath technology in February 2011 through its acquisition of ReVascular Therapeutics.
